Splint Versus Steroid Randomized Trial
Study Details
Study Description
Brief Summary
The primary aim is to compare the effectiveness of splinting versus steroid injection in improving the DASH scores in participants diagnosed with De Quervain's tenosynovitis over a period of 6 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The primary hypothesis is that steroid injection into the first dorsal compartment is more effective compared with splinting at 3 months.
The secondary hypothesis is that steroid injection yields better clinical outcomes compared with splinting at 1 month, 3 months and 6 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Randomized: Steroid injection 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment. |
Drug: Hydrocortisone-Lidocaine
Intervention will be done on the same day based on the randomization.
For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.
For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.
|
| Other: Randomized: Splint a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks |
Other: Splint
Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.
For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.
|
Outcome Measures
Primary Outcome Measures
- Quick Disability of Arm, Shoulder, Hand (QuickDASH) [6 months]
Our co- primary outcome would be QuickDash. QuickDash is a disability score we use for the upper limb where the higher score indicates greater disability and severity. We would expect a decrease in QuickDash scores following a success in the treatment measure. The resultant score is reported on a scale of 0 to 100, where 0 represents no disability and 100 represents total disability
- Patients who have recovered from De Quervain's Tenosynovitis [6 months]
The other primary outcomes would be the number of patients who have completely recovered from De Quervain's tenosynovitis. This will be determined by the global improvement the patient feels that will be ranked on a 7 point Likert scale (1: very much worse, 2: much worse, 3:slightly worse, 4:no change, 5:slightly better, 6:much better, 7:completely resolved).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed diagnosis of de Quervain's tenosynovitis based on the de Quervain's screening tool (DQST) with scores ≥ 5 (refer to table 1)
-
No prior treatment
-
Above 21 years of age
Exclusion Criteria:
-
Allergy to steroid (triamcinolone acetate) or local anaesthetic (lignocaine)
-
History of work related trauma
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- National University Hospital, Singapore
Investigators
- Principal Investigator: Renita Sirisena, National University Hospital, Singapore
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2019/00246